

AUGUST 15, 1989

VOLUME 264

NUMBER 23

ISSN 0021-9258

JBCHA3 264(23) 13369-13962 (1989)

THE

SCIENCE-
ENGINEERING

LIBRARY

Journal of Biological Chemistry

Published by the American Society for Biochemistry
and Molecular Biology

FOUNDED BY CHRISTIAN A. HERTER

ESTABLISHED IN 1905 AS THE CHRISTIAN A. HERTER MEMORIAL FUND

Copyright © 1989 by the American Society for Biochemistry and Molecular Biology, Inc.
428 East Preston St., Baltimore, MD 21202 U.S.A.

CONTENTS*

MINIREVIEW

- 13369 **Proteoglycans in cell regulation.**
Erkki Ruoslahti

COMMUNICATIONS

- 13373 **Mapping of the active site tyrosine of eukaryotic DNA topoisomerase I.**
Wai-kwong Eng, Sunil D. Pandit, and Rolf Sternglanz
- 13377 **Purification and partial amino acid sequence of osteogenin, a protein initiating bone differentiation.**
Frank P. Luyten, Noreen S. Cunningham, S. Ma, N. Muthukumar, R. Glenn Hammonds, W. Byron Nevins, William I. Wood, and A. H. Reddi
- 13381 **New crystal form of recombinant murine interferon- β .**
Susumu Matsuda, Toshiya Senda, Susumu Itoh, Genji Kawano, Hiroshi Mizuno, and Yukio Mitsui
- 13383 **Requirements for the translational repression of ferritin transcripts in wheat germ extracts by a 90-kDa protein from rabbit liver.**
Peter H. Brown, Susan Daniels-McQueen, William E. Walden, Maria M. Patino, Livia Gaffield, Debbie Bielser, and Robert E. Thach
- 13387 **Hamster fibroblasts defective in thrombin-induced mitogenesis. A selection for mutants in phosphatidylinositol metabolism and other functions.**
Heidi M. Rath, Glenn A. R. Doyle, and David F. Silbert
- 13391 **Isolation and characterization of a yeast strain carrying a mutation in the mitochondrial promoter for COX2.**
Vicki L. Cameron, Thomas D. Fox, and Robert O. Poyton
- 13395 **Sequence requirements for apolipoprotein B RNA editing in transfected rat hepatoma cells.**
Michael S. Davies, Simon C. Wallis, Donna M. Driscoll, Judy K. Wynne, Gareth W. Williams, Lyn M. Powell, and James Scott
- 13399 **Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C.**
David J. McConkey, Pia Hartzell, Mikael Jondal, and Sten Orrenius
- 13403 **Cleavage of parathyroid hormone in macrophage endosomes illustrates a novel pathway for intracellular processing of proteins.**
Stephanie Diment, Kevin J. Martin, and Philip D. Stahl

ARTICLES

- 13407 **cDNA derived amino acid sequence of the 86-kDa subunit of the Ku antigen.**
Mariana Yaneva, Juan Wen, Antonia Ayala, and Richard Cook
- 13412 **Genomic organization and chromosomal localization of the human cathepsin G gene.**
Patricia A. Hohn, Nicholas C. Popescu, Robin D. Hanson, Guy Salvesen, and Timothy J. Ley
- 13420 **The use of α_2 -antiplasmin as a model for the demonstration of complex reversibility in serpins.**
Bie-Hue Shieh, Jan Potempa, and James Travis

- 13424 **Characterization of diphtheria toxin-induced lesions in liposomal membranes. An evaluation of the relationship between toxin insertion and "channel" formation.**
Gui-sen Jiang, Rikki Solow, and Valerie W. Hu
- 13430 **Regulation of citric acid cycle by calcium.**
Bang Wan, Kathryn F. LaNoue, Joseph Y. Cheung, and Russell C. Scaduto, Jr.
- 13440 **The structure of a molybdopterin precursor. Characterization of a stable, oxidized derivative.**
Jean L. Johnson, Margot M. Wuebbens, and K. V. Rajagopalan
- 13448 **Tocopheroxyl radical persistence and tocopherol consumption in liposomes and in vitamin E-enriched rat liver mitochondria and microsomes.**
Rolf J. Mehlhorn, Satoshi Sumida, and Lester Packer
- 13453 **The interaction site for tamoxifen aziridine with the bovine estrogen receptor.**
Thomas Ratajczak, Steven P. Wilkinson, Martine J. Brockway, Roland Hähnel, Robert L. Moritz, Geoffrey S. Begg, and Richard J. Simpson
- 13460 **The ligand-binding conformation of M₂, 46,000 mannose 6-phosphate-specific receptor. Acquisition of binding activity during *in vitro* synthesis.**
Annette Hille, Abdul Waheed, and Kurt von Figura
- 13468 **Lipoproteins may provide fatty acids necessary for human lymphocyte proliferation by both low density lipoprotein receptor-dependent and -independent mechanisms.**
Jennifer A. Cuthbert and Peter E. Lipsky
- 13475 **Characterization of a novel membrane glycoprotein involved in platelet activation.**
Judith L. Scott, Stephanie M. Dunn, Boquan Jin, Andrew J. Hillam, Steven Walton, Michael C. Berndt, Andrew W. Murray, Geoffrey W. Krissansen, and Gordon F. Burns
- 13483 **Complementary DNA encoding core protein II of human mitochondrial cytochrome bc₁ complex. Substantial diversity in deduced primary structure from its yeast counterpart.**
Yoshitaka Hosokawa, Hiroshi Suzuki, Haruo Toda, Morimitsu Nishikimi, and Takayuki Ozawa
- 13489 **Molecular genetic analysis of the regulatory and catalytic domains of protein kinase C.**
Kozo Kaibuchi, Yasuo Fukumoto, Naohisa Oku, Yoshimi Takai, Ken-ichi Arai, and Masa-aki Muramatsu
- 13497 ***In vitro* multimerization of von Willebrand factor is triggered by low pH. Importance of the propolyptide and free sulfhydryls.**
Tanya N. Mayadas and Denisa D. Wagner
- 13504 **Role of bestatin-sensitive exopeptidases in the intracellular degradation of hepatic proteins.**
Violeta Botbol and Oscar A. Scornik
- 13510 **Single strand DNA cleavage reaction of duplex DNA by *Drosophila* topoisomerase II.**
Maxwell P. Lee, Miriam Sander, and Tao-shih Hsieh
- 13519 **Glutathione regulates interleukin-2 activity on cytotoxic T-cells.**
Chi-Ming Liang, Nancy Lee, Debra Cattell, and Shu-Mei Liang

* The CONTENTS arranged by Subject Categories will be found immediately following these CONTENTS.
Full Instructions to Authors will be found in (1989) *J. Biol. Chem.* 264, 11527-11537, and reprints may be obtained from the editorial office.

- 13524 **Coupling of exogenous receptors to phospholipase C in *Xenopus* oocytes through pertussis toxin-sensitive and -insensitive pathways. Cross-talk through heterotrimeric G-proteins.**
Thomas M. Moriarty, Stuart C. Sealfon, Donna J. Carty, James L. Roberts, Ravi Iyengar, and Emmanuel M. Landau
- 13531 **Manganese-dependent peroxidase from *Phanerochaete chrysosporium*. Primary structure deduced from cDNA sequence.**
Elizabeth A. Pease, Andrawis Andrawis, and Ming Tien
- 13536 **Epimerization of 3-hydroxyacyl-CoA esters in rat liver. Involvement of two 2-enoyl-CoA hydratases.**
J. Kalervo Hiltunen, Päivi M. Palosaari, and Wolf-H. Kunau
- 13541 **Consensus sequences for early iodination and homogenization in human thyroglobulin.**
Luis Lamas, Peggy C. Anderson, Jay W. Fox, and John T. Dunn
- 13546 **The identification and characterization of collagen receptors involved in HeLa cell-substratum adhesion.**
Michael L. Lu, Dorothy A. Beacham, and Bruce S. Jacobson
- 13559 **Identification of a hemolysin from *Actinobacillus pleuropneumoniae* and characterization of its channel properties in planar phospholipid bilayers.**
Guy Lalonde, Thomas V. McDonald, Phyllis Gardner, and Peter D. O'Hanley
- 13565 **Structural organization of the gene for the $\alpha 1$ chain of human type IV collagen.**
Raija Soininen, Merja Huotari, Arupa Ganguly, Darwin J. Prockop, and Karl Tryggvason
- 13572 **Identification of two serine residues involved in agonist activation of the β -adrenergic receptor.**
Catherine D. Strader, Mari Rios Candelore, Wendy S. Hill, Irving S. Sigal, and Richard A. F. Dixon
- 13579 **Primary structure and organization of the gene for a procaryotic, cell envelope-located serine proteinase.**
Pieter Vos, Guus Simons, Roland J. Siezen, and Willem M. de Vos
- 13586 **Regulation of proacrosin conversion in isolated guinea pig sperm acrosomal apical segments.**
Thomas D. Noland, Linda S. Davis, and Gary E. Olson
- 13591 **Identification of receptors for platelet-activating factor in rat Kupffer cells.**
Wei Chao, Heling Liu, Michael DeBuysere, Donald J. Hanahan, and Merle S. Olson
- 13599 **Fumarate reductase mutants of *Escherichia coli* that lack covalently bound flavin.**
Michael Blaut, Katherine Whittaker, Adriana Valdovinos, Brian A. C. Ackrell, Robert P. Gunsalus, and Gary Cecchini
- 13605 **Agonist-induced regulation of inositol tetrakisphosphate isomers and inositol pentakisphosphate in adrenal glomerulosa cells.**
Tamás Balla, Albert J. Baukal, László Hunyady, and Kevin J. Catt
- 13612 **Kinetic characterization of the Ca^{2+} -pumping ATPase of cardiac sarcolemma in four states of activation.**
Deborah A. Dixon and Duncan H. Haynes
- 13623 **Binding, internalization, and intracellular processing of proteins interacting with recycling receptors. A kinetic analysis.**
Željko Bajzer, Andrew C. Myers, and Stanimir Vuk-Pavlovic
- 13632 **Kinetic study of internalization and degradation of ^{125}I -labeled follicle-stimulating hormone in mouse Sertoli cells and its relevance to other systems.**
Akitoshi Shimizu and Seiichiro Kawashima
- 13639 **Appendix. Derivation and application of mathematical model for kinetics of ^{125}I -follicle-stimulating hormone bound to receptors.**
Akitoshi Shimizu and Seiichiro Kawashima
- 13642 **Reconstitution of epidermal growth factor receptor transmodulation by platelet-derived growth factor in Chinese hamster ovary cells.**
Janice L. Countaway, Núria Gironès, and Roger J. Davis
- 13648 **Structure of the phosphorylated N-linked oligosaccharides from the *mnn9* and *mnn10* mutants of *Saccharomyces cerevisiae*.**
Luis M. Hernandez, Lun Ballou, Eugenio Alvarado, Pei-Kuo Tsai, and Clinton E. Ballou
- 13660 **Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor $\beta 1$ precursor. Expression and characterization of mutant proteins.**
Amy M. Brunner, Hans Marquardt, Alison R. Malacko, Mario N. Lioubin, and Anthony F. Purchio
- 13665 ***Myxococcus xanthus* msDNA-Mx162 exists as a complex with proteins.**
Manickam Viswanathan, Masayori Inouye, and Sumiko Inouye
- 13672 **Sulfonylurea binding to adipocyte membranes and potentiation of insulin-stimulated hexose transport.**
Andrea Martz, Inho Jo, and Chan Y. Jung
- 13679 **The mechanism of cAMP-induced glucocorticoid receptor expression. Correlation to cellular glucocorticoid response.**
Yu Dong, Marie Aronsson, Jan-Åke Gustafsson, and Sam Okret
- 13684 **Deuterium isotope effect measurements on the interactions of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidase B.**
Susanne Ottoboni, Patricia Caldera, Anthony Trevor, and Neal Castagnoli, Jr.
- 13689 **Biosynthesis of ependymins from goldfish brain.**
Andreas Königstorfer, Sylvia Sterrer, and Werner Hoffmann
- 13693 **L-Canavanine incorporation into vitellogenin and macromolecular conformation.**
Gerald A. Rosenthal, Jean-Marc Reichhart, and Jules A. Hoffmann
- 13697 **Regulation of the product of a possible human cell cycle control gene CDC2Hs in B-cells by α -interferon and phorbol ester.**
N. Shaun B. Thomas
- 13701 **Immunological identification of 1,25-dihydroxyvitamin D_3 receptors in human promyelocytic leukemia cells (HL-60) during homologous regulation.**
Youngsook Lee, Masaaki Inaba, Hector F. DeLuca, and William S. Mellon
- 13706 **Identification of functionally important residues in the DNA binding region of the Mnt repressor.**
Kendall L. Knight and Robert T. Sauer
- 13711 ***In vivo* phosphorylation and activation of ribosomal protein S6 kinases during *Xenopus* oocyte maturation.**
Eleanor Erikson and James L. Maller
- 13718 **Direct photolabeling of the cGMP-stimulated cyclic nucleotide phosphodiesterase.**
Steven D. Stroop, Harry Charbonneau, and Joseph A. Beavo
- 13726 **Post-translational suppression of expression of intestinal brush border enzymes by fructose.**
E. Michael Danielsen

- 13730 Differential glucocorticoid regulation of collagen mRNAs in human dermal fibroblasts. Kelloid-derived and fetal fibroblasts are refractory to down-regulation.
Shirley B. Russell, Joel S. Trupin, Jeanne C. Myers, Alan H. Broquist, Joan C. Smith, Marvin E. Myles, and James D. Russell
- 13736 A monoclonal antibody that triggers deacylation of an intermediate thrombin-antithrombin III complex.
Shinji Asakura, Michio Matsuda, Nobuhiko Yoshida, Shigeharu Terukina, and Hiroshi Kihara
- 13740 Characterization of two distinct positive cis-acting elements in the mouse $\alpha 1$ (III) collagen promoter.
E. Cristy Ruteshouser and Benoit de Crombrughe
- 13745 Lymphocyte surface antigen L25 is a member of the integrin receptor superfamily.
Bradley W. McIntyre, Elizabeth L. Evans, and John L. Bednarczyk
- 13751 Purification, characterization, and transcriptional analyses of RNA polymerases from *Rhodobacter sphaeroides* cells grown chemoheterotrophically and photoheterotrophically.
Janice W. Kansy and Samuel Kaplan
- 13760 Purification of a glycosyl-phosphatidylinositol-specific phospholipase D from human plasma.
Michael A. Davitz, Judy Hom, and Sergio Schenkman
- 13765 Purification of a specific repressor of ferritin mRNA translation from rabbit liver.
William E. Walden, Maria Mercedes Patino, and Livia Gaffield
- 13770 Purification and characterization of an erythrocyte membrane protein complex carrying Duffy blood group antigenicity. Possible receptor for *Plasmodium vivax* and *Plasmodium knowlesi* malaria parasite.
Asok Chaudhuri, Valerie Zbrzezna, Carol Johnson, Margaret Nichols, Pablo Rubinstein, W. Laurence Marsh, and A. Oscar Pogo
- 13775 Mutation of the predicted ATP binding site inactivates both activities of isocitrate dehydrogenase kinase/phosphatase.
Constance S. Stueland, Timothy P. Ikeda, and David C. LaPorte
- 13780 A 14-kilodalton selenium-binding protein in mouse liver is fatty acid-binding protein.
Mohinder P. Bansal, Richard G. Cook, Keith G. Danielson, and Daniel Medina
- 13785 Localization of the membrane-associated CTP:phosphocholine cytidyltransferase in Chinese hamster ovary cells with an altered membrane composition.
Janice N. Morand and Claudia Kent
- 13793 The role of selenium-dependent and selenium-independent glutathione peroxidases in the formation of prostaglandin $F_{2\alpha}$.
Yang Hong, Chun-Hai Li, John R. Burgess, Mei Chang, Amy Salem, Kotteazeth Sri Kumar, and C. Channa Reddy
- 13801 Functional inactivation and structural disruption of human α_2 -macroglobulin by neutrophils and eosinophils.
Vivek Y. Reddy, Salvatore V. Pizzo, and Stephen J. Weiss
- 13810 Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation.
Sherida E. Tollefsen, Rosemarie Lajara, Robert H. McCusker, David R. Clemmons, and Peter Rotwein
- 13818 Activation of protein kinase C by naturally occurring ether-linked diglycerides.
David A. Ford, Ryohei Miyake, Paul E. Glaser, and Richard W. Gross
- 13825 Purification of a hepatic S6 kinase from cycloheximide-treated rats.
Daniel J. Price, Raphael A. Nemenoff, and Joseph Avruch
- 13834 A library of oligosaccharide probes (neoglycolipids) from N-glycosylated proteins reveals that conglutinin binds to certain complex-type as well as high mannose-type oligosaccharide chains.
Tsuguo Mizuochi, Ruth W. Loveless, Alexander M. Lawson, Wengang Chai, Peter J. Lachmann, Robert A. Childs, Steffen Thiel, and Ten Feizi
- 13840 Synthesis and accumulation of hyaluronic acid and proteoglycans in the mouse cumulus cell-oocyte complex during follicle-stimulating hormone-induced mucification.
Antonietta Salustri, Masaki Yanagishita, and Vincent C. Hascall
- 13848 Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of β -galactoside $\alpha 2,6$ -sialyltransferase.
Eryn Ujita Lee, Jurgen Roth, and James C. Paulson
- 13856 Regulation of proliferating cell nuclear antigen during the cell cycle.
Gilbert F. Morris and Michael B. Mathews
- 13865 Cloning and expression of human steroid-sulfatase. Membrane topology, glycosylation, and subcellular distribution in BHK-21 cells.
Christina Stein, Annette Hille, Johannes Seidel, Simon Rijnbout, Abdul Waheed, Bernhard Schmidt, Hans Geuze, and Kurt von Figura
- 13873 Cloning and expression of a smooth muscle caldesmon.
Joseph Bryan, Michio Imai, Robyn Lee, Paul Moore, Richard G. Cook, and Wen-Gin Lin
- 13880 Purification and properties of *Methanobacterium thermoautotrophicum* DNA photolyase.
Andreas Kiener, Intisar Husain, Aziz Sancar, and Christopher Walsh
- 13888 Cloning and sequence analysis of the *Escherichia coli* *metH* gene encoding cobalamin-dependent methionine synthase and isolation of a tryptic fragment containing the cobalamin-binding domain.
Ruma V. Banerjee, Nancy L. Johnston, James Kenneth Sobeski, Prasanta Datta, and Rowena G. Matthews
- 13896 Identification of a muscle-specific enhancer within the 5'-flanking region of the human myoglobin gene.
Blythe H. Devlin, Franklin C. Wefald, William E. Kraus, Tammie S. Bernard, and R. Sanders Williams
- 13902 Biosynthesis and posttranslational modifications of protein kinase C in human breast cancer cells.
Christoph Borner, Ireos Filipuzzi, Markus Wartmann, Urs Eppenberger, and Dorian Fabbro
- 13910 The human $\alpha 2$ (XI) collagen (COL11A2) chain. Molecular cloning of cDNA and genomic DNA reveals characteristics of a fibrillar collagen with differences in genomic organization.
Tomoatsu Kimura, Kathryn S. E. Cheah, Samuel D. H. Chan, Vincent C. H. Lui, Marie-Genevieve Mattei, Michel van der Rest, Keiro Ono, Ellen Solomon, Yoshifumi Ninomiya, and Bjørn R. Olsen
- 13917 Modification of AlF_7^- and receptor-stimulated phospholipase C activity by G-protein $\beta\gamma$ subunits.
José Luis Boyer, Gary L. Waldo, Tony Evans, John K. Northup, C. Peter Downes, and T. Kendall Harden
- 13923 Human pulmonary surfactant protein (SP-A), a protein structurally homologous to C1q, can enhance FcR- and CR1-mediated phagocytosis.
Andrea J. Tenner, Susan L. Robinson, Jenny Borchelt, and Jo Rae Wright

- 13929 Two genes encode the major membrane-associated protein of methanol-induced peroxisomes from *Candida boidinii*.
Lisa J. Garrard and Joel M. Goodman
- 13938 Molecular basis of the liver and lung disease associated with the $\alpha 1$ -antitrypsin deficiency allele *M_{malton}*.
David T. Curiel, Mark D. Holmes, Hiroshi Okayama, Mark L. Brantly, Claus Vogelmeier, William D. Travis, Larue E. Stier, Warren H. Perks, and Ronald G. Crystal
- 13946 Additional members of the rat liver lamin polypeptide family. Structural and immunological characterization.
Scott H. Kaufmann

- 13956 Agonist regulation of β -adrenergic receptor mRNA. Analysis in S49 mouse lymphoma mutants.
John R. Hadcock, Manuel Ros, and Craig C. Malbon

ADDITIONS AND CORRECTIONS

- 13962 A transport system for coenzyme A in isolated rat heart mitochondria. Vol. 262 (1987) 11607-11610.
Arun G. Tahliliani and James R. Neely
- 13962 The α -lytic protease gene of *Lysobacter enzymogenes*. The nucleotide sequence predicts a large prepro-peptide with homology to pro-peptides of other chymotrypsin-like enzymes. Vol. 263 (1988) 16586-16590.
David M. Epstein and Pieter C. Wensink

GENERAL INFORMATION FOR 1989

Submit all manuscripts in triplicate to

Editor, The Journal of Biological Chemistry
9650 Rockville Pike
Bethesda, MD 20814, U.S.A.

Accepted manuscripts will be published with the implicit understanding that the author(s) will pay a charge per page (miniprint supplement excluded). Current page charges may be obtained by contacting the JBC Office. Under exceptional circumstances, when no source of grant or other support exists, the author(s) may apply, at the time of submission, for a grant-in-aid to Chairman, Publications Committee, American Society for Biochemistry and Molecular Biology, Inc., 9650 Rockville Pike, Bethesda, MD 20814. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for page charges.

Queries on matters of general editorial policy, requests for reprints of the "Instructions to Authors," or of the "Editorial Policy and Practices," or for permission to reproduce any part of a previously published article should be directed to the Journal Editorial Office in Bethesda, telephone 301-530-7150.

The Journal of Biological Chemistry publishes papers on a broad range of topics of interest to biochemists. The views expressed are those of the author(s) and not of The Journal of Biological Chemistry or the American Society for Biochemistry and Molecular Biology.

The Journal of Biological Chemistry is copyrighted by the American Society for Biochemistry and Molecular Biology, Inc. ∞ Printed on acid-free paper effective with Volume 254, Issue No. 1 (1979). Reprographic copying beyond that permitted by Sections 107 or 108 of the

U.S. Copyright Law is allowed, provided that the \$1.50 per-copy fee is paid through the Copyright Clearance Center, 21 Congress Street, Salem, MA 01970. Reproduction of any portion of an article for subsequent republication requires permission of the copyright owner. Requests should be made in writing to the American Society for Biochemistry and Molecular Biology, Inc., Attn.: Editorial Office, 9650 Rockville Pike, Bethesda, MD 20814, and should include a statement of intended use as well as explicit specifications of the material to be reproduced.

Address all correspondence and orders relative to subscriptions and back copies to: THE JOURNAL OF BIOLOGICAL CHEMISTRY, 428 EAST PRESTON STREET, BALTIMORE, MD 21202, U.S.A., telephone 301-528-4255. Subscriptions are entered on a calendar year basis only. Requests for termination of subscriptions will be honored with proportional refunds less a \$10 cancellation charge. Allow at least six weeks for address changes. Claims for replacement copies must be received within four months of the issue date.

The Journal of Biological Chemistry (ISSN 0021-9258) is published three times per month by the American Society for Biochemistry and Molecular Biology, Inc., 428 East Preston Street, Baltimore, MD 21202, U.S.A. Volume 264: United States, \$490; other countries, \$615. Single copy: United States, \$19.00; other countries, \$22.00. Special subscription rates are available to members, graduate students, and postdoctoral fellows for personal use only. Qualifying forms are available from the ASBMB Office, 9650 Rockville Pike, Bethesda, MD 20814. Second class postage paid at Baltimore, MD 21202, U.S.A. and at additional mailing offices. Send address changes to The Journal of Biological Chemistry at 428 East Preston Street, Baltimore, MD 21202, U.S.A.

Site-directed Mutagenesis of Cysteine Residues in the Pro Region of the Transforming Growth Factor β 1 Precursor

EXPRESSION AND CHARACTERIZATION OF MUTANT PROTEINS*

(Received for publication, March 27, 1989)

Amy M. Brunner, Hans Marquardt, Alison R. Malacko, Mario N. Lioubin, and Anthony F. Purchio†

From *Oncogen*, Seattle, Washington 98121

Three cysteine residues are located in the pro region of the transforming growth factor β 1 (TGF- β 1) precursor at amino acid positions 33, 223, and 225. Previous studies (Gentry, L. E., Lioubin, M. N., Purchio, A. F., and Marquardt, H. (1988) *Mol. Cell. Biol.* 8, 4162-4168) with purified recombinant TGF- β 1 (rTGF- β 1) precursor produced by Chinese hamster ovary (CHO) cells revealed that Cys-33 can form a disulfide bond with at least 1 cysteine residue in mature TGF- β 1, contributing to the formation of a 90-110-kDa protein. We now show that Cys-223 and Cys-225 form interchain disulfide bonds. Site-directed mutagenesis was used to change these Cys codons to Ser codons, and mutant constructs were transfected into COS cells. Analysis of recombinant proteins by immunoblotting showed that by substituting Cys-33 the 90-110-kDa protein is not formed, and thus, more mature dimer (24 kDa) is obtained, corresponding to a 3- to 5-fold increase in biological activity. Substitution of Cys-223 and/or Cys-225 resulted in near wild-type levels of mature TGF- β 1. Furthermore, cells transfected with plasmid coding for Ser at positions 223 and 225 expressed only monomeric precursor proteins and released bioactive TGF- β 1 that did not require acid activation, suggesting that dimerization of the precursor pro region may be necessary for latency.

(19) TGF- β 1 have predicted that the 112-residue chain of TGF- β 1 is proteolytically cleaved from the COOH terminus of a 390-amino acid prepro-TGF- β 1. The precursor contains a typical hydrophobic signal peptide sequence and three potential N-linked glycosylation sites.

Simian TGF- β 1 cDNA has been expressed to high levels in CHO cells, resulting in the secretion of both precursor and mature forms of TGF- β 1 (20). Subsequent studies have revealed that the rTGF- β 1 precursor is glycosylated at all three sites and phosphorylated at mannose residues (21, 22). Recent experiments suggest that carbohydrate addition to the pro region of the TGF- β 1 precursor is necessary for transport and secretion of mature polypeptide.² The pro region of the precursor may also be important in the regulation of TGF- β 1. Several studies (23-25) have shown that most cell types secrete TGF- β 1 in a biologically inactive form. rTGF- β 1 is also secreted in a latent form which can be activated by acidification (20). In addition, a latent complex has been isolated from platelets (26, 27) in which mature TGF- β 1 is noncovalently associated with the pro region and an unidentified protein, and further studies (28) have indicated that carbohydrate structures in the pro region are necessary for latency.

Interestingly, purified recombinant precursor was shown to consist of pro-TGF- β 1 (residues 30-390; a in Fig. 2A), the pro region of the precursor (residues 30-278; b in Fig. 2A), and mature TGF- β 1 (residues 279-390; c in Fig. 2A) interlinked by disulfide bonds (29). The most abundant form of the rTGF- β 1 precursor was found to contain two homodimeric subunits bridged by intersubunit disulfide bonds between Cys-33 in the TGF- β 1 pro region subunit and cysteine residues in the mature TGF- β 1 subunit to form a 90-110-kDa protein. This suggests that more biologically active TGF- β 1 dimer might be generated if Cys-33 was substituted, allowing more of the processed mature TGF- β 1 to be released from the precursor complex.

In addition to Cys-33, 2 other cysteine residues are located in the pro region at positions 223 and 225. In this report, we present assignment of two intermolecular disulfide bonds between residues 223 and 225, respectively. We also examine the significance of these 3 cysteines in dimerization, processing, and latency of TGF- β 1 through the use of site-directed mutagenesis followed by expression of mutant constructs in COS cells.

EXPERIMENTAL PROCEDURES

Characterization of CNBr Peptide M(134-253)₂—rTGF- β 1 precursor synthesized by CHO cells (20) was purified by gel permeation chromatography, cleaved with CNBr, and the peptides purified fol-

² X. Sha, A. M. Brunner, A. F. Purchio, and L. E. Gentry, manuscript in preparation.

Transforming growth factor β 1 (TGF- β 1)¹ belongs to a family of polypeptides that regulate cell growth and differentiation (for reviews see Refs. 1-3). Although originally defined by its ability to stimulate the anchorage-independent growth of nontumorigenic fibroblasts (4), TGF- β 1 has been shown to inhibit proliferation of a variety of cells including endothelial cells (5, 6), T and B lymphocytes (7-9), and keratinocytes (10). This polypeptide's diverse effects also include stimulation of fibronectin and collagen synthesis and secretion (11, 12), induction of squamous cell differentiation (13), and inhibition of myogenic differentiation (14).

Biologically active TGF- β 1 is a 24-kDa homodimer interlinked by at least one disulfide bond (15, 16). Analyses of cDNA clones coding for human (17), simian (18), and murine

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence should be addressed: Oncogen, 3005 First Ave., Seattle, WA 98121. Tel.: 206-728-4800.

¹ The abbreviations used are: TGF- β , transforming growth factor β ; rTGF- β 1, recombinant TGF- β 1; SDS, sodium dodecyl sulfate; CHO, Chinese hamster ovary; HPLC, high performance liquid chromatography.

lowing previously described methods (29). Cys-containing peptides were detected after reduction with tributylphosphine and coupling with ammonium 7-fluorobenzo-2-oxo-1,3-diazole-4-sulfonate (30) and purified to homogeneity by reversed-phase HPLC on a μ Bondapak C₁₈ column (Waters Associates Inc., Milford, MA) (29).

Peptides were separated on 15% SDS-polyacrylamide gels and stained with Coomassie Brilliant Blue R-250 as described (31). Disulfide-linked peptides were analyzed with an Applied Biosystems 475A Sequencer. Phenylthiohydantoin were separated on an Applied Biosystems 120A PTH-analyzer as described (29).

Site-directed Mutagenesis—Mutagenesis was performed using the Amersham *in vitro* mutagenesis system, according to the manufacturer's protocol. The template for mutagenesis consisted of the *Pst*I-*Eco*RI fragment from pTGF- β -2 (18), coding for simian TGF- β 1 precursor, inserted into the *Pst*I and *Eco*RI sites of M13mp18. The oligonucleotides used to construct the mutants were synthesized on an Applied Biosystems DNA synthesizer and are shown in Fig. 2B. Each encodes a Ser residue in place of the indicated Cys residue. In each case, 5–10 plaques were screened for the desired mutation by single track sequencing and the final mutant characterized by further sequencing using the dideoxy chain termination method (32).

Construction of Expression Vectors and Transient Expression—The mutant genes were subcloned into the expression vector π H3M (33), lacking the polylinker between *Xho*I sites. π H3M was cleaved with *Xho*I, filled in with Klenow fragment, and digested with *Hind*III. Each mutant cDNA was excised from the M13-derived replicative form by digestion with *Eco*RI, followed by repair to blunt ends with Klenow fragment and digestion with *Hind*III, and then ligated into the *Hind*III-*Xho*I (blunt) vector. Expression plasmid pTGF- β 1^{S33} codes for the protein prepro-TGF- β 1^{S33}, containing a serine at position 33 of the TGF- β 1 precursor in place of the wild-type cysteine residue. Similarly, pTGF- β 1^{S223}, pTGF- β 1^{S225}, and pTGF- β 1^{S223/225} code for prepro-TGF- β 1^{S223}, prepro-TGF- β 1^{S225}, and prepro-TGF- β 1^{S223/225}, respectively, with superscripts indicating the positions where cysteine residues have been replaced with serines.

For transient expression of the mutant gene products, the plasmids were transfected into COS cells by the DEAE-dextran/chloroquine method as described (34). Each transfection was performed at least three times. COS cells were transfected at 30–60% confluency with 25 μ g of DNA/100-mm plate in a total volume of 5 ml for 2.5 h at 37 °C. After a 48-h incubation in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, the medium was replaced with serum-free Dulbecco's modified Eagle's medium. Transfected cells were incubated an additional 72 h prior to supernatant collection.

Analysis of Mutant Proteins—Serum-free supernatants from transfected COS cells were dialyzed against 0.2 M acetic acid. TGF- β 1 activity was determined by growth inhibition of mink lung epithelial cells (MvLu; CCL-64; American Type Culture Collection) as described previously (35). Highly purified recombinant TGF- β 1 (29) synthesized by CHO cells and possessing the same specific activity as natural TGF- β 1 was used as a standard. Typically, 80–120 pg of TGF- β 1/ml resulted in 50% inhibition.

Secreted TGF- β 1 proteins were analyzed by immunoblotting (20, 36). Briefly, 0.8 ml of acid-dialyzed supernatant was lyophilized, resuspended in 50 μ l of sample buffer, fractionated on 7.5–17.5% gradient SDS-polyacrylamide gels, and transferred to nitrocellulose. TGF- β 1 proteins were detected with anti-peptide antibodies specific for mature TGF- β 1 (anti-TGF- β 1_{369–381}) or the pro region of the TGF- β 1 precursor (anti-TGF- β 1_{81–94}) (20).

RESULTS

TGF- β 1 Precursor Cysteine Residues 223 and 225 Form Interchain Disulfide Bonds—Purified rTGF- β 1 precursor was cleaved at methionine residues with CNBr, and the resulting peptides were purified by gel permeation chromatography. Cys-containing peptides were detected according to the procedure of Sueyoshi *et al.* (30) and purified to homogeneity by reversed-phase HPLC. Edman degradation data located the positions of the CNBr peptides in the sequence of the TGF- β 1 precursor. Peptide M(134–253)₂ contained a 2 half-cystine residues, as determined by amino acid analysis, but lacked free thiol groups, as determined with a fluorescent thiol-specific reagent under nonreducing conditions. Disulfide bridges in M(134–253)₂ were assigned by demonstrating the dimeric character of this peptide. As shown in Fig. 1, the size





Fig. 1. SDS-polyacrylamide gel analysis of purified cyanogen bromide peptide M(134–253). M(134–253) was fractionated on a 15% SDS-polyacrylamide gel under nonreducing (A) or reducing (B) conditions and stained with Coomassie Brilliant Blue R-250. Size markers are indicated in kilodaltons.



| Mutant | Oligonucleotide |
|------------------------------------|----------------------------|
| TGF- β 1 ^{S33} | ACTATCCACCAGCAAGACTAT |
| TGF- β 1 ^{S223} | TAGCGCCACAGCTCCTGTGA |
| TGF- β 1 ^{S225} | CACGTGCTCCTCTGACAGCAA |
| TGF- β 1 ^{S223/225} | TAGCGCCACAGCTCCTCTGACAGCAA |

Fig. 2. A, line diagram of prepro-TGF- β 1. Pro-TGF- β 1, the pro region of the precursor, and mature TGF- β 1 are indicated by lines a, b, and c, respectively. Cys (C) residues in the pro region are indicated. Mannose 6-phosphate-containing sites (P) and nonphosphorylated sites (N) of N-linked glycosylation are shown. B, TGF- β 1 precursor mutants. Superscripts indicate the amino acid position of the Ser substitutions. Unmatched nucleotides are in **bold print** and new Ser codons are underlined.

of M(134–253)₂ was estimated at 41 kDa under nonreducing conditions, whereas under reducing conditions M(134–253) had a mass of 24 kDa. The change in size of M(134–253)₂ following reduction identifies two intermolecular disulfide bonds linking identical chains, consistent with a single amino acid sequence for peptide M(134–253)₂ and the determination of 2 half-cystine residues by amino acid analysis. The pro region of rTGF- β 1 precursor secreted by CHO cells has been shown to be glycosylated at Asn-82, -136, and -176 (21, 22). Therefore, the observed heterogeneity of M(134–253)₂ on SDS-polyacrylamide gels (Fig. 1) most likely reflects glycosylation at Asn-136 and Asn-176.

Analysis of Proteins Encoded by Mutant TGF- β 1 Genes—Three cysteine residues are located in the pro region of the TGF- β 1 precursor at amino acid positions 33, 223, and 225. A line diagram of the TGF- β 1 precursor is displayed in Fig. 2A. Using simian TGF- β 1 cDNA as a template, each Cys codon was separately changed to a Ser codon by site-directed mutagenesis. Oligonucleotides used to direct the mutagenesis are shown in Fig. 2B. In each case, a single base pair change

accomplished the Cys to Ser codon switch. A double mutant in which both Cys-223 and Cys-225 were changed to Ser codons was also constructed.

The mutant TGF- β 1 cDNAs were inserted into the expression vector π H3M (33) and transiently expressed in COS cells. Serum-free supernatants from the transfected cells were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting with a mixture of antibodies specific for the pro and mature regions of the TGF- β 1 precursor (Fig. 3). Under reducing conditions (Fig. 3A), the mutant proteins appeared identical to the wild type. Antibodies detected the 12-kDa monomer (c in Fig. 2A) as well as 44–56-kDa and 30–42-kDa precursor forms (a and b in Fig. 2A). In addition, the immunoblot shown in Fig. 3A indicates that the absolute amount of secreted TGF- β 1 proteins was not significantly affected by the mutations.

Differences between mutant and wild-type TGF- β 1 proteins were readily apparent when examined under nonreducing conditions (Fig. 3B). Mature TGF- β 1 dimer (24 kDa) was present in all transfectant supernatants. However, cells transfected with pTGF- β 1^{S33} yielded increased levels of the 24-kDa dimer compared to wild-type transfectants (Fig. 3B, lanes 3 and 4), whereas pTGF- β 1^{S223}, pTGF- β 1^{S225}, and pTGF- β 1^{S223/225} transfectants produced near wild-type levels. This increase in 24-kDa dimer did not appear to be a result of increased protein synthesis/secretion or increased cleavage of mature TGF- β 1 from pro-TGF- β 1, since immunoblotting under reducing conditions indicated that pTGF- β 1 and pTGF- β 1^{S33} transfectants secreted approximately equal amounts of both mature TGF- β 1 and precursor forms (Fig. 3A).

In addition, the TGF- β 1^{S33} proteins did not form the 90–110-kDa precursor complex as did wild-type proteins (Fig. 3B). Instead, a 130 to 150-kDa and 75 to 85-kDa species were seen (Fig. 3B, lane 4). As shown in Fig. 4, the TGF- β 1^{S33} 130–150-kDa proteins were recognized by both pro region- and mature-specific antibodies and most likely represent a dimeric complex of pro-TGF- β 1^{S33} linked by disulfide bonds. The




FIG. 3. Immunoblot of TGF- β 1 mutant proteins secreted by transfected COS cells. Transfected cells were incubated in serum-free media (5 ml/100-mm dish) 48 h post-transfection for 72 h. Serum-free supernatants were collected, dialyzed *versus* 0.2 M acetic acid, and 0.8 ml of each supernatant was fractionated on 7.5–17.5% SDS-polyacrylamide gels under reducing (A) or nonreducing (B) conditions. Immunoblots were probed with a mixture of pro region (anti-TGF- β 1_{81–94}) and mature (anti-TGF- β 1_{369–381}) specific anti-peptide antibodies. COS cells were transfected with vector (π H3M) only (lane 2, A and B) or with vector encoding TGF- β 1 (lane 3, A and B), TGF- β 1^{S33} (lane 4, A and B), TGF- β 1^{S223} (lane 5, A and B), TGF- β 1^{S225} (lane 6, A and B) and TGF- β 1^{S223/225} (lane 7, A and B). Lane 1 contains supernatant from nontransfected COS cells. Size standards are indicated in kilodaltons. Results are representative of three separate experiments.




FIG. 4. Identification of mutant TGF- β 1 precursor and mature proteins. Supernatants from COS cells transfected with π H3M (lane 2, A and B), pTGF- β 1 (lane 3, A and B), pTGF- β 1^{S33} (lane 4, A and B), pTGF- β 1^{S223} (lane 5, A and B), pTGF- β 1^{S225} (lane 6, A and B), or pTGF- β 1^{S223/225} (lane 7, A and B) were collected and processed as described in the legend to Fig. 3. Samples were fractionated on nonreducing 7.5–17.5% SDS-polyacrylamide gels and immunoblotted with antibodies specific for mature (A) sequences (anti-TGF- β 1_{369–381}) or the pro region (B) (anti-TGF- β 1_{81–94}). Lane 1 contains nontransfected COS cell supernatant. Size standards are indicated in kilodaltons.

rTGF- β 1 proteins secreted by COS cells transfected with plasmids encoding wild-type or mutant TGF- β 1 precursor appear identical when analyzed under reducing conditions (Fig. 3A); therefore, the 130–150-kDa complex observed under nonreducing conditions (Fig. 3B, lanes 3 and 4) most likely results from structural changes in the molecules due to disulfide bonding. The 75–85-kDa polypeptide was only detected by pro region-specific antibody (Fig. 4B, lane 4) and probably represents a dimer of the pro region of the TGF- β 1^{S33} precursor.

In contrast, mutant proteins encoded by pTGF- β 1^{S223} and pTGF- β 1^{S225} formed the 90–110-kDa precursor complex (lanes 5 and 6 in Figs. 3B, 4A, and 4B), although some monomeric precursor forms were also present. The slight difference in molecular weight between the pro-TGF- β 1^{S223} and pro-TGF- β 1^{S225} 90–110-kDa precursor complexes (Fig. 4B, lanes 5 and 6) may be due to variations in glycosylation or differences in folding due to altered disulfide bonding. Antibodies specific for the pro region of the TGF- β 1 precursor detected 44–56-kDa and 30–42-kDa proteins (Fig. 4B, lanes 5 and 6), whereas

TABLE I

Amount of bioactive TGF- β 1 secreted by COS cell transfectants

COS cells were transfected with plasmids encoding TGF- β 1 and variants; 48 h post-transfection, supernatants were replaced with serum-free medium; 72 h later, conditioned media were collected and assayed directly (–acid) or following dialysis versus 0.2 M acetic acid (+acid) for growth inhibition of CCL64 cells as described under “Experimental Procedures.”

| | +acid | –acid |
|------------------------------------|-------|-------|
| | ng/ml | |
| TGF- β 1 | 90.3 | 4.7 |
| TGF- β 1 ^{S33} | 304.8 | 12.5 |
| TGF- β 1 ^{S223} | 98.4 | 20.3 |
| TGF- β 1 ^{S225} | 77.9 | 11.2 |
| TGF- β 1 ^{S223/225} | 87.9 | 65.3 |

antibody specific for mature sequences detected only the 44–56-kDa species (Fig. 4A, lanes 5 and 6). Cells transfected with pTGF- β 1^{S223/225} yielded only monomeric precursor forms (lane 7 in Figs. 3B, 4A, and 4B), yet mature TGF- β 1 was still proteolytically cleaved from pro-TGF- β 1^{S223/225} and formed the 24-kDa dimer.

All Mutant TGF- β 1 Precursors Generate Biologically Active TGF- β 1—Biological activity corresponded well with the amount of 24-kDa mature TGF- β 1 detected by immunoblotting (Figs. 3B and 4A). Following acid activation, supernatants from cells transfected with plasmids pTGF- β 1^{S223}, pTGF- β 1^{S225}, and pTGF- β 1^{S223/225} yielded near wild-type levels of inhibitory activity (Table I). In contrast, pTGF- β 1^{S33} transfectants yielded approximately 3-fold more activity than pTGF- β 1 transfectants. These observations were consistent among separately performed transfections, with pTGF- β 1^{S33} transfected COS cells always generating 3- to 5-fold more inhibitory activity than cells transfected with wild-type plasmid pTGF- β 1.

Mutant TGF- β 1^{S223/225} Yields Biologically Active TGF- β 1 without Prior Acidification—rTGF- β 1 synthesized by COS cells is secreted in a latent form (Table I). Similarly, TGF- β 1 is released by platelets as a latent high molecular weight complex (26, 27). Activation of rTGF- β 1 can be achieved by acidification. Both TGF- β 1 and TGF- β 1^{S33} were $\geq 90\%$ biologically inactive prior to acidification, whereas TGF- β 1^{S223} and TGF- β 1^{S225} were $\geq 80\%$ inactive. However, TGF- β 1^{S223/225} was at least 70% active without acid treatment, and in separate experiments (data not shown) levels of activity before and after acidification were equal. This suggests that the pro region of the TGF- β 1 precursor is necessary to confer latency of rTGF- β 1. Platelet-derived TGF- β 1 was recently shown (26, 27) to be noncovalently associated with a complex involving the dimeric precursor pro region and another protein. The TGF- β 1^{S223/225} precursor exists only as a monomer (lane 7 in Figs. 3B, 4A, and 4B); thus, conformational changes resulting from the substitution of both Cys-223 and Cys-225 may not allow the interactions between mature TGF- β 1 and its precursor which result in latency.

DISCUSSION

Previous studies (20) have shown that CHO cells expressing wild-type simian TGF- β 1 cDNA produce a 90–110-kDa precursor form. Subsequent studies (29) have revealed that this complex consists of pro-TGF- β 1 (residues 30–390), the pro region of the precursor (residues 30–278) and mature TGF- β 1 (residues 279–390) (a, b, and c, respectively in Fig. 2A) linked by intersubunit disulfide bonds. Specifically, it was shown that Cys-33 forms a disulfide bond with a least 1 half-cystine residue in mature TGF- β 1. In this report, we show that substitution of Cys-33 with a serine residue does not

affect the proteolytic processing of prepro-TGF- β 1, but does result in the generation of more mature 24-kDa dimer (Fig. 3B). This correlates with an approximately 3- to 5-fold increase in bioactivity (Table I) and appears to be the result of the dissolution of the 90–110-kDa complex. Apparently, pTGF- β 1^{S33} transfectants generated more mature 24-kDa dimer, because the pro region of the TGF- β 1^{S33} precursor was unable to disulfide bond to processed mature TGF- β 1.

In addition, we demonstrated that the other 2 cysteines located in the pro region at amino acid positions 223 and 225 form interchain disulfide bonds. Substitution of either of these cysteines with a serine still resulted in the formation of the wild-type 90–110-kDa protein; however, some monomeric precursor forms were also present (Fig. 4). Substitution of both Cys-223 and Cys-225 resulted in the production of only monomeric precursor forms, yet mature TGF- β 1 was still proteolytically cleaved from the precursor and able to form a bioactive dimer. This maturation appeared to be as efficient as that of the wild-type TGF- β 1 precursor.

Although the 3 cysteines located in the pro region of the TGF- β 1 precursor appear nonessential for the production of mature rTGF- β 1, they may be important in the regulation of TGF- β 1. Although dimerization of the precursor seems unnecessary for proteolytic cleavage of mature TGF- β 1, it may be required for latency. Cells transfected with a plasmid coding for preproTGF- β 1^{S223/225} released TGF- β 1 in an active form (Table I). Recently (26, 27), latent TGF- β 1 has been purified from human platelets as a high molecular weight complex in which the dimeric pro portion of the TGF- β 1 precursor is disulfide-linked to an unknown protein and noncovalently associated with mature TGF- β 1. In the CHO cell expression system, there is no evidence for another protein which could form a complex with the precursor and mature forms of TGF- β 1 (20, 29). This is also likely to be true in the COS cell system, since the rTGF- β 1 precursor and mature forms produced by COS cells appear similar if not identical to those produced by CHO cells when examined by immunoblotting. Our results indicate that mature rTGF- β 1 is noncovalently associated with the precursor pro region, and when the pro region cannot form a dimer, latency is not conferred. This is most likely due to the disruption of the noncovalent association. However, at this time, we cannot rule out the possibility that mature TGF- β 1 is noncovalently associated with the monomeric TGF- β 1^{S223/225} pro region, forming a complex that is not latent because mature sequences necessary for activity are sufficiently exposed.

Recent studies (28) have indicated that carbohydrate structures in the pro region are involved in noncovalently binding TGF- β 1 to form a latent complex. Perhaps dimerization of the pro region provides the proper three-dimensional structure and stability for such interactions. Little is known about the regulation of TGF- β 1 activity *in vivo*. Since most cell types release TGF- β 1 in a latent form (23–25), activation of the latent complex appears to be a critical regulatory step. A clearer understanding of the nature of this latency should aid in determining physiological mechanisms of activation.

The high level of expression and secretion of recombinant TGF- β 1 may lead to an unnatural cross-linking, making the disulfide linkage between Cys-33 and half-cystine residues located in the mature polypeptide an artifact of the expression system. On the other hand, it may be indicative of a regulatory role for Cys-33 through interactions with other proteins. This seems especially plausible in view of the disulfide-linked complex isolated from platelets (26, 27).

Thus, the 3 cysteines located in the pro portion of the precursor may influence the maturation and activation of

TGF- β 1 in two ways. Cys-223 and Cys-225 allow the precursor to form a dimer and subsequently interact with mature TGF- β 1 in a noncovalent manner to form a latent complex, whereas Cys-33 may act by disulfide bonding to mature TGF- β 1 and/or other proteins to modulate the action of TGF- β 1.

cDNA clones have been obtained for two other TGF- β s, TGF- β 2 (37-40) and TGF- β 3 (41, 42). The TGF- β s are ~70-80% identical in their COOH-terminal mature regions, whereas the pro regions share only ~30-45% identity. However, the 3 cysteine residues in the pro region are conserved among the three TGF- β s, with TGF- β 2 and TGF- β 3 each containing additional cysteines in this region. Recombinant TGF- β 2 has recently been expressed (43), and as is the case with TGF- β 1, acid-activation was required for bioactivity. Experiments are in progress to investigate whether cysteines in the TGF- β 2 and TGF- β 3 precursors function in a manner similar to those in TGF- β 1 and whether their pro regions are also involved in regulating the action of the mature growth factor.

Acknowledgments—We gratefully acknowledge Michael Neubauer for performing the DNA sequencing and Scott Austin for synthesis of the oligonucleotides.

REFERENCES

- Sporn, M. B., Roberts, A. B., Wakefield, L. M., and de Crombrughe, B. (1987) *J. Cell Biol.* **105**, 1039-1045
- Keski-Oja, J., Leof, E. B., Lyons, R. M., Coffey, R. J., Jr., and Moses, H. L. (1987) *J. Cell. Biochem.* **33**, 95-107
- Massague, J. (1987) *Cell* **49**, 437-438
- Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., and Sporn, M. B. (1981) *Proc. Natl. Acad. Sci. U. S. A.* **78**, 5339-5343
- Frater-Schroder, M., Muller, G., Birchmeier, W., and Bohlen, P. (1986) *Biochem. Biophys. Res. Commun.* **137**, 295-302
- Heimark, R. L., Twardzik, D. R., and Schwartz, S. M. (1986) *Science* **223**, 1070-1080
- Kehrl, J. H., Roberts, A. B., Wakefield, L. M., Jakowlew, S., Sporn, M. B., and Fauci, A. S. (1986) *J. Immunol.* **137**, 3855-3860
- Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., Sporn, M. B., and Fauci, A. S. (1986) *J. Exp. Med.* **163**, 1037-1050
- Kasid, A., Bell, G. I., and Director, E. P. (1988) *J. Immunol.* **141**, 690-698
- Coffey, R. J., Jr., Sipes, N. J., Bascum, C. C., Graves-Deal, R., Pennington, C. Y., Weissman, B. E., and Moses, H. L. (1988) *Cancer Res.* **48**, 1596-1602
- Ignatz, R. A., and Massagué, J. (1986) *J. Biol. Chem.* **261**, 4337-4345
- Centrella, M., McCarthy, T. L., and Canalis, E. (1987) *J. Biol. Chem.* **262**, 2869-2874
- Mausi, T., Wakefield, L. M., Lechner, J. F., LaVeck, M. A., Sporn, M. B., and Harris, C. C. (1986) *Proc. Natl. Acad. Sci. U. S. A.* **83**, 2438-2442
- Massague, J., Cheifetz, S., Endo, T., and Nadal-Ginard, B. (1986) *Proc. Natl. Acad. Sci. U. S. A.* **83**, 8206-8210
- Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., and Sporn, M. B. (1983) *J. Biol. Chem.* **258**, 7155-7160
- Frolik, C. A., Dart, L. L., Meyers, C. A., Smith, D. M., and Sporn, M. B. (1983) *Proc. Natl. Acad. Sci. U. S. A.* **80**, 3676-3680
- Derynck, R., Jarret, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., Assoian, R. K., Roberts, A. B., Sporn, M. B., and Goeddel, D. V. (1985) *Nature* **316**, 701-705
- Sharples, K., Plowman, G. D., Rose, T. M., Twardzik, D. R., and Purchio, A. F. (1987) *DNA* **6**, 239-244
- Derynck, R., Jarret, J. A., Chen, E. Y., and Goeddel, D. V. (1986) *J. Biol. Chem.* **261**, 4377-4379
- Gentry, L. E., Webb, N. R., Lim, G. J., Brunner, A. M., Ranchalis, J. E., Twardzik, D. R., Lioubin, M. N., Marquardt, H., and Purchio, A. F. (1987) *Mol. Cell. Biol.* **7**, 3418-3427
- Brunner, A. M., Gentry, L. E., Cooper, J. A., and Purchio, A. F. (1988) *Mol. Cell. Biol.* **8**, 2229-2232
- Purchio, A. F., Cooper, J. A., Brunner, A. M., Lioubin, M. N., Gentry, L. E., Kovacina, K. S., Roth, R. A., and Marquardt, H. (1988) *J. Biol. Chem.* **263**, 14211-14215
- Lawrence, D. A., Pircher, R., Krycève-Martinerie, C., and Jullien, P. (1984) *J. Cell. Physiol.* **121**, 184-188
- Pircher, R., Jullien, P., and Lawrence, D. A. (1986) *Biochem. Biophys. Res. Commun.* **136**, 30-37
- Wakefield, L. M., Smith, D. M., Masui, T., Harris, C. C., and Sporn, M. B. (1987) *J. Cell Biol.* **105**, 965-975
- Miyazono, K., Hellman, U., Wernstedt, C., and Heldin, C.-H. (1988) *J. Biol. Chem.* **263**, 6407-6415
- Wakefield, L. M., Smith, D. M., Flanders, K. C., and Sporn, M. B. (1988) *J. Biol. Chem.* **263**, 7646-7654
- Miyazono, K., and Heldin, C.-H. (1989) *Nature* **338**, 158-160
- Gentry, L. E., Lioubin, M. N., Purchio, A. F., and Marquardt, H. (1988) *Mol. Cell. Biol.* **8**, 4162-4168
- Sueyoshi, T., Miyata, T., Iwanaga, S., Toyooka, T., and Imai, K. (1985) *J. Biochem. (Tokyo)* **97**, 1811-1813
- Laemmli, U. K. (1970) *Nature* **227**, 680-685
- Sanger, F., Nicklen, S., and Coulson, A. R. (1977) *Proc. Natl. Acad. Sci. U. S. A.* **84**, 8573-8577
- Aruffo, A., and Seed, B. (1987) *Proc. Natl. Acad. Sci. U. S. A.* **84**, 8573-8577
- Seed, B., and Aruffo, A. (1987) *Proc. Natl. Acad. Sci. U. S. A.* **84**, 3365-3369
- Ikedo, T., Lioubin, M. N., and Marquardt, H. (1987) *Biochemistry* **26**, 2406-2410
- Burnette, W. N. (1981) *Anal. Biochem.* **112**, 195-203
- Madisen, L., Webb, N. R., Rose, T. M., Marquardt, H., Ikeda, T., Twardzik, D., Seyedin, S., and Purchio, A. F. (1988) *DNA* **7**, 1-8
- Hanks, S. K., Armour, R., Baldwin, J. H., Maldonado, F., Spiess, J., and Holley, R. W. (1988) *Proc. Natl. Acad. Sci. U. S. A.* **85**, 79-82
- deMartin, R., Haendler, B., Hoeffler-Warbinek, R., Gaugitsch, H., Wrann, M., Schlusener, H., Seifert, J. M., Bodmer, S., Fontana, A., and Hofer, E. (1987) *EMBO J.* **6**, 3673-3677
- Webb, N. R., Madisen, L., Rose, T. M., and Purchio, A. F. (1988) *DNA* **7**, 493-497
- Ten Dijke, P., Hansen, P., Iwata, K. K., Pieler, C., and Foulkes, J. G. (1988) *Proc. Natl. Acad. Sci. U. S. A.* **85**, 4715-4719
- Derynck, R., Lindquist, P. B., Lee, A., Wen, D., Tamm, J., Graycar, J. L., Rhee, L., Mason, A. J., Miller, D. A., Coffey, R. J., Moses, H. L., and Chen, E. L. (1988) *EMBO J.* **7**, 3737-3743
- Madisen, L., Farrand, A. L., Lioubin, M. N., Marzowski, J., Knox, L. B., Webb, N. R., Lim, J., and Purchio, A. F. (1989) *DNA* **8**, 205-212